Liquisolid systems as a novel approach in formulation and manufacturing of solid dosage forms: Challenges and perspectives
Abstract
Liquisolid systems are a novel, promising platform for the production of solid dosage forms with a high liquid content, i.e. dispersion of the drug in a suitable, hydrophilic, non-volatile liquid vehicle or liquid drug. This technology requires conventional, but highly porous excipients (carrier and coating material in the appropriate ratio) able to absorb/adsorb liquid medication, resulting in both good flowability and acceptable compression properties. This approach has shown great potential to improve the dissolution rate and bioavailability of poorly soluble drugs, and has been recognized as a good alternative to common, more complex and expensive techniques. A variety of applications of this simple technique have been investigated recently, including the preparation of: modified release tablets, orally disintegrating tablets, solid dosage forms with liquid herbal extracts, etc. This emerging technology has numerous advantages, and the most important are: simplicity, cost-effectiveness, applicability in large scale production and environmental friendliness. However, it is accompanied by certain challenges as well, such as limited applicability in the case of highly dosed drugs. This article aims to give a comprehensive overview of recent progress regarding the potential applications of this technology, as well as to give an insight into the new liquisolid-based techniques intending to further support its commercial applicability.
References
1. Göke K, Lorenz T, Repanas A, Schneider F, Steiner D, Baumann K, et al. Novel strategies for the formulation and processing of poorly water-soluble drugs. Eur J Pharm Biopharm. 2018;126:40–56.
2. Bertoni S, Hasa D, Albertini B, Perissutti B, Grassi M, Voinovich D, Passerini N. Better and greener: sustainable pharmaceutical manufacturing technologies for highly bioavailable solid dosage forms. Drug Deliv Transl Res. 2022;12(8):1843–1858.
3. Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017;248:71–95.
4. Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B. 2021;11(8):2505–2536.
5. Spireas S, Jarowski C, Rohera B. Powdered solution technology: principles and mechanism. Pharm Res. 1992;9(10):1351-1358.
6. Spireas S, Bolton SM. Liquisolid systems and methods for preparing same. United States patent 5,800,834. 1998.
7. Spireas S. Liquisolid systems and methods for preparing same. United States patent 6,423,339 B1. 2002.
8. Aleksić I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load. Arh farm. 2022;72:61–76.
9. Aleksić I, German Ilić I, Cvijić S, Parojčić J. An investigation into the influence of process parameters and formulation variables on compaction properties of liquisolid systems. AAPS PharmSciTech. 2020;21:242.
10. Vranikova B, Gajdziok J, Vetchy D. Modern evaluation of liquisolid systems with varying amounts of liquid phase prepared using two different methods. Biomed Res Int. 2015;2015:608435.
11. Vasiljević I, Turković E, Nenadović S, Mirković M, Zimmer A, Parojčić J, Aleksić I. Investigation into liquisolid system processability based on the SeDeM Expert System approach. Int J Pharm. 2021;605:120847.
12. Pezzini BR, Beringhs AO, Ferraz HG, Silva MAS, Stulzer HK, Sonaglio D. Liquisolid technology applied to pellets: Evaluation of the feasibility and dissolution performance using felodipine as a model drug. Chem Eng Res Des. 2016;110:62–69.
13. Javadzadeh Y, Siahi MR, Asnaashari S, Nokhodchi A. An investigation of physicochemical properties of piroxicam liquisolid compacts. Pharm Dev Technol. 2007;12:337–343.
14. Vraníková B, Svačinová P, Marushka J, Brokešová J, Holas O, Tebbens JD, Šklubalová Z. The importance of the coating material type and amount in the preparation of liquisolid systems based on magnesium aluminometasilicate carrier. Eur J Pharm Sci. 2021;165:105952.
15. Aleksić I, Vasiljević I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. Paper presented at: 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2021 May 11-14, virtual conference.
16. Javadzadeh Y, Musaalrezaeia L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm. 2008;362:102–108.
17. Vraníková B, Gajdziok J. Evaluation of sorptive properties of various carriers and coating materials for liquisolid systems. Acta Pol Pharm. 2015;72(3):539-549.
18. Hentzschel CM, Sakmann A, Leopold CS. Suitability of various excipients as carrier and coating materials for liquisolid compacts. Drug Dev Ind Pharm. 2011;37(10):1200–1207.
19. Jadhav NR, Irny PV, Patil US. Solid state behavior of progesterone and its release from Neusilin US2 based liquisolid compacts. J Drug Deliv Sci Technol. 2017;38:97–106.
20. Komala DR, Janga KY, Jukanti R, Bandary S. Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. J Drug Deliv Sci Technol. 2015;30:232–241.
21. Elkordy AA, Essa EA, Dhuppad S, Jammigumpula P. Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles. Int J Pharm. 2012;434(1-2):122–132.
22. Lu M, Xing H, Jiang J, Chen X, Yang T, Wang D, Ding P. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017;12(2):115–123.
23. Vraníková B, Pavloková S, Gajdziok J. Experimental design for determination of effects of superdisintegrant combinations on liquisolid system properties. J Pharm Sci. 2017;106(3):817–825.
24. Javadzadeh Y, Navimipour BJ, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm. 2007;341:26-34.
25. Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: speed it up, slow it down. Expert Opin Drug Deliv. 2011;8(2):191–205.
26. Molaei M-A, Osouli-Bostanabad K, Adibkia K, Shokri J, Asnaashari S, Javadzadeh Y. Enhancement of ketoconazole dissolution rate by the liquisolid technique. Acta Pharm. 2018;68(3):325–336.
27. Badawy МА, Kamel АО, Sammour ОА. Use of biorelevant media for assessment of a poorly soluble weakly basic drug in the form of liquisolid compacts: in vitro and in vivo study. Drug Delivery. 2016;23(3):818–827.
28. Kurek M, Woyna-Orlewicz K, Khalid MH, Jachowicz R. Optimization of furosemide liquisolid tablets preparation process leading to their mass and size reduction. Acta Pol Pharm. 2016;73(5):1325–1331.
29. Lu M, Xing H, Yang T, Yu J, Yang Z, Sun Y, Ding P. Dissolution enhancement of tadalafil by liquisolid technique. Pharm Dev Technol. 2017;22:77–89.
30. Jaipakdee N, Limpongsa E, Sripanidkulchai B, Piyachaturawat P. Preparation of Curcuma comosa tablets using liquisolid techniques: In vitro and in vivo evaluation. Int J Pharm. 2018;553:157–168.
31. Suliman AS, Anderson RJ, Elkordy AA. Preparation of novel optimum liquisolid compacts via incorporating water granulation process to enhance the powder characterizations and dissolution behavior of a poorly soluble drug: Norfloxacin. Powder Technol. 2019;354:259–70.
32. Bonthagarala B, Dasari V, Kotra V, Swain S, Beg S. Quality-by design based development and characterization of pioglitazone loaded liquisolid compact tablets with improved biopharmaceutical attributes. J Drug Deliv Sci Technol. 2019;51:345–55.
33. Azharshekoufeh LB, Shokri J, Adibkia K, Javadzadeh Y. Liquisolid technology: What it can do for NSAIDs delivery? Colloids Surf B. 2015;136:185–191.
34. Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Il Farmaco. 2005;60(4):361–5.
35. Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm. 2009;73(3):373–384.
36. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts, J Pharm Pharm Sci. 2005;8(1):18–25.
37. Nagabandi V, Tadikonda R, Jayaveera KN. Formulation development and evaluation of liquisolid systems to improve the dissolution rate of ketoprofen. Int J Biomed Res. 2011;2(10):530–541.
38. Vittal GV, Deveswaran R, Bharath S, Basavaraj BV, Madhavan V. Formulation and characterization of ketoprofen liquisolid compacts by Box-Behnken design. Int J Pharm Investig. 2012;2(3):150–6.
39. Vajir S, Sahu V, Ghuge N, Bang P, BV B. Enhancement of dissolution rate of poorly water soluble diclofenac sodium by liquisolid technique. Int J Pharm Chem Sci. 2012;1(3):1338-1349.
40. Thadkala K, Voruganti S, Reddy Badari S, Chandra S. Enhancement of dissolution rate of nimesulide by liquisolid compaction technique. Int J Pharm Tech Res. 2012;4(3):1294-1302.
41. Spireas S, Wang T, Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm. 1999;25(2):163–8.
42. Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. Eur J Pharm Biopharm. 2008;69:342–7.
43. Fahmy R, Kassem M. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm. 2008;69(3):993–1003.
44. Hentzschel CM, Alnaief M, Smirnova I, Sakmann A, Leopold CS. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm. 2012;80(1):130–135.
45. Hani U, Suresh Babu M, Fatima A, Tauqeer S. Formulation and evaluation of liquisolid compacts of flunarizine hydrochloride. Int J Pharm Technol. 2015;6(3):7115–7130.
46. Gong W, Wang Y, Sun L, Yang J, Shan L, Yang M, et al. Development of itraconazole liquisolid compact: effect of polyvinylpyrrolidone on the dissolution properties. Curr Drug Deliv. 2016;13(3):452–61.
47. Khaled KA, Asiri YA, El-Sayed YM. In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs. Int J Pharm. 2001;222:1–6.
48. Khames A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug Deliv. 2017;24(1):328–338.
49. Khames A. Formulation and characterization of eplerenone nanoemulsion liquisolids, an oral delivery system with higher release rate and improved bioavailability. Pharmaceutics. 2019;11(1):40.
50. Jhaveri M, Nair AB, Shah J, Jacob S, Patel V, Mehta T. Improvement of oral bioavailability of carvedilol by liquisolid compact: optimization and pharmacokinetic study. Drug Deliv and Transl Res. 2020. doi: 10.1007/s13346-020-00734-3.
51. Sheta NM, Elfeky YA, Boshra SA. Cardioprotective efficacy of silymarin liquisolid in isoproterenol prompted myocardial infarction in rats. AAPS PharmSciTech. 2020;21:81.
52. Patel K, Doddapaneni R, Patki M, Sekar V, Bagde A, Singh M. Erlotinib-valproic acid liquisolid formulation: evaluating oral bioavailability and cytotoxicity in erlotinib-resistant non-small cell lung cancer cells. AAPS PharmSciTech. 2019;20:135.
53. Jyoti J, Anandhakrishnan NK, Singh SK, Kumar B, Gulati M, Gowthamarajan K, et al. A three-pronged formulation approach to improve oral bioavailability and therapeutic efficacy of two lipophilic drugs with gastric lability. Drug Deliv and Transl Res. 2019;9:848–865.
54. Basalious EB, El-Sebaie W, El-Gazayerly O. Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization andin vitro/in vivo studies. Pharm Dev Technol. 2013;18(2):407–416.
55. Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTs): Recent advances and perspectives. Biomed Res Int. 2021. doi: 10.1155/2021/6618934.
56. Egla M, Hammid SNAA. Design zolmitriptan liquisolid orodispersible tablets and their in vitro evaluation. J Chem Pharm Res. 2016;8(11):232-242.
57. Moqbel HA, ElMeshad AN, El-Nabarawi MA. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets. Drug Dev Ind Pharm. 2016;43(5):742–750.
58. Nokhodchi A, Aliakbar R, Desai S, Javadzadeh Y. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release. Colloids Surf B Biointerfaces. 2010;79:262-9.
59. Khanfar M, Sheikh Salem M, Kaddour F. Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique. Pharm Dev Technol. 2013;19(1):103–115.
60. Rashad AA, Nageeb El-Helaly S, Abd El Rehim RT, El-Gazayerly ON. Chronological delivery of antihypertensive drugs in bilayered core-in-cup buccoadhesive tablets: In vitro and in vivo evaluation. AAPS PharmSciTech. 2020;21(1):21.
61. European Medicines Agency [Internet]. Good practice guide on risk minimisation and prevention of medication errors [cited 2022 Aug 29]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf.
62. World Health Organisation. WHO guidelines on good herbal processing practices for herbal medicines, In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-second report, Annex 1 (WHO Technical Report Series, No. 1010). Geneva, 2018.
63. Baranauskaite J, Kopustinskiene DM, Masteikova R, Gajdziok J, Baranauskas A, Bernatoniene J. Effect of liquid vehicles on the enhancement of rosmarinic acid and carvacrol release from oregano extract liquisolid compacts. Colloids Surf A Physicochem Eng Asp. 2018;539:280–290.
64. Jaipakdee N, Limpongsa E, Sripanidkulchai B, Piyachaturawat P. Preparation of Curcuma comosa tablets using liquisolid techniques: In vitro and in vivo evaluation. Int J Pharm. 2018;553:157–168.
65. Sirithunyalug B, Saenjum C, Charumanee S, Sivamaruthi B, Chaiyasut C, Sirithunyalug J, et al. Development of colorectal-targeted dietary supplement tablets containing natural purple rice bran oil as a colorectal chemopreventive. Nutrients. 2018;10(4):444.
66. Sheta NM, Elfeky YA, Boshra SA. Cardioprotective efficacy of silymarin liquisolid in isoproterenol prompted myocardial infarction in rats. AAPS PharmSciTech. 2020;21(3):81.
67. Kurhajec S, Kostelanská K, Pavloková S, Vetchý D, Wolaschka T, Gajdziok J, Franc A. Stabilized antioxidative plant extracts formulated by liquisolid technique. J Drug Deliv Sci Technol. 2020;6:102022.
68. Kostelanská K, Kurhajec S, Pavloková S, Vetchý D, Gajdziok J, Franc A. Technology of processing plant extracts using an aluminometasilicate porous carrier into a solid dosage form. Pharmaceutics. 2022;14(2):248.
69. El-Hammadi M, Awad N. Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release. AAPS PharmSciTech. 2011;13(1):53–58.
70. Chella N, Narra N, Rama RT. Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. J Drug Deliv. 2014;2014:1–10.
71. Khames A. Liquisolid technique: a promising alternative to conventional coating for improvement of drug photostability in solid dosage forms. Expert Opin Drug Deliv. 2013;10(10):1335–1343.
72. Javaheri H, Carter P, Elkordy AA. Wet granulation to overcome liquisolid technique issues of poor flowability and compactibility: A study to enhance glibenclamide dissolution. J Pharm Drug Dev. 2014;2(3):301.
73. De Espíndola B, Beringhs AO, Sonaglio D, Stulzer HK, Silva MAS, Ferraz HG, et al. Liquisolid pellets: A pharmaceutical technology strategy to improve the dissolution rate of ritonavir. Saudi Pharm J. 2019;27(5):702–712.
74. dos Santos Fonseca AB, Beringhs AOR, Ferraz HG, Stulzer HK, Sonaglio D, Pezzini BR. Liquisolid pellets: Mixture experimental design assessment of critical quality attributes influencing the manufacturing performance via extrusion-spheronization. J Drug Deliv Sci Technol. 2020;57:101630.
75. Taghizadeh Z, Rakhshani S, Jahani V, Rajabi O, Haghighi HM, Abbaspour M. Preparation and in vitro characterization of carvacrol pellets by combination of liquisolid technique and extrusion-spheronization. J Drug Deliv Sci Technol. 2021;61:102232.
76. Lam M, Ghafourian T, Nokhodchi A. Liqui-Pellet: the emerging next-generation oral dosage form which stems from liquisolid concept in combination with pelletization technology. AAPS PharmSciTech. 2019;20(6):231.
77. Lam M, Commandeur D, Maniruzzaman M, Tan DK, Nokhodchi, A. The crucial effect of water and co-solvent on liqui-pellet pharmaceutical performance. Adv Powder Technol. 2020;31:1903–1914.
78. Lam M, Ghafourian T, Nokhodchi A. Optimising the release rate of naproxen liqui-pellet: A new technology for emerging novel oral dosage form. Drug Deliv Transl Res. 2020;10:43–58.
79. Lam M, Nokhodchi A. Factors affecting performance and manufacturability of naproxen Liqui-Pellet. DARU J Pharm Sci. 2020;28:567–579.
80. Lam M, Asare-Addo K, Nokhodchi A. Liqui-tablet: The innovative oral dosage form using the newly developed. AAPS PharmSciTech. 2021;22:85.
81. Lam M, Nokhodchi A. Producing high‑dose liqui‑tablet (ketoprofen 100 mg) for enhanced drug release using novel liqui‑mass technology. J Pharm Innov. 2021. doi: 10.1007/s12247-021-09561-6.
82. Lam M, Nashed N, Nokhodchi A. Liqui-mass technology as a novel tool to produce sustained release liqui-tablet made from liqui-pellets. Pharmaceutics. 2021;13:1049.
83. Nazem NM, Shokri J, Nourani N, Zangi AR, Lam M, Nokhodchi A, et al. Combining liquisolid and co-grinding techniques to enhance the dissolution rate of celecoxib. J Pharm Innov. 2022; 1–10. doi: 10.1007/s12247-022-09641-1
84. Tong Y, Wang Y, Yang M, Yang J, Chen L, Chu X, et al. Systematic development of self-nanoemulsifying liquisolid tablets to improve the dissolution and oral bioavailability of an oily drug, vitamin K1. Pharmaceutics. 2018;10(3):96.
